Acasti Pharma Stock Working Capital
| ACSTDelisted Stock | USD 3.37 0.01 0.30% |
Acasti Pharma fundamentals help investors to digest information that contributes to Acasti Pharma's financial success or failures. It also enables traders to predict the movement of Acasti Stock. The fundamental analysis module provides a way to measure Acasti Pharma's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Acasti Pharma stock.
Acasti |
Acasti Pharma Company Working Capital Analysis
Acasti Pharma's Working Capital is a measure of company efficiency and operating liquidity. The working capital is usually calculated by subtracting Current Liabilities from Current Assets. It is an important indicator of the firm ability to continue its normal operations without additional debt obligations. .
More About Working Capital | All Equity Analysis
Working Capital | = | Current Assets | - | Current Liabilities |
Current Acasti Pharma Working Capital | 22.33 M |
Most of Acasti Pharma's fundamental indicators, such as Working Capital, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Acasti Pharma is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Working Capital can be positive or negative, depending on how much of current debt the company is carrying on its balance sheet. In general terms, companies that have a lot of working capital will experience more growth in the near future since they can expand and improve their operations using existing resources. On the other hand, companies with small or negative working capital may lack the funds necessary for growth or future operation. Working Capital also shows if the company has sufficient liquid resources to satisfy short-term liabilities and operational expenses.
CompetitionIn accordance with the company's disclosures, Acasti Pharma has a Working Capital of 22.33 M. This is 94.75% lower than that of the Pharmaceuticals sector and 95.85% lower than that of the Health Care industry. The working capital for all United States stocks is 98.49% higher than that of the company.
Acasti Working Capital Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Acasti Pharma's direct or indirect competition against its Working Capital to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Acasti Pharma could also be used in its relative valuation, which is a method of valuing Acasti Pharma by comparing valuation metrics of similar companies.Acasti Pharma is currently under evaluation in working capital category among its peers.
Acasti Fundamentals
| Return On Equity | -0.19 | |||
| Return On Asset | -0.12 | |||
| Current Valuation | 11.17 M | |||
| Shares Outstanding | 10.14 M | |||
| Shares Owned By Insiders | 38.39 % | |||
| Shares Owned By Institutions | 21.22 % | |||
| Number Of Shares Shorted | 154.19 K | |||
| Price To Earning | 15.34 X | |||
| Price To Book | 0.58 X | |||
| Price To Sales | 208.39 X | |||
| Gross Profit | 120 K | |||
| EBITDA | (11.3 M) | |||
| Net Income | (12.85 M) | |||
| Cash And Equivalents | 38.39 M | |||
| Cash Per Share | 0.86 X | |||
| Total Debt | 11.56 M | |||
| Debt To Equity | 0.01 % | |||
| Current Ratio | 11.13 X | |||
| Book Value Per Share | 5.86 X | |||
| Cash Flow From Operations | (12.33 M) | |||
| Short Ratio | 3.84 X | |||
| Earnings Per Share | (1.43) X | |||
| Target Price | 7.97 | |||
| Beta | 1.52 | |||
| Market Capitalization | 36.5 M | |||
| Total Asset | 73.3 M | |||
| Retained Earnings | (211.12 M) | |||
| Working Capital | 22.33 M | |||
| Current Asset | 11.33 M | |||
| Current Liabilities | 1.14 M | |||
| Net Asset | 73.3 M |
About Acasti Pharma Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Acasti Pharma's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Acasti Pharma using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Acasti Pharma based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Thematic Opportunities
Explore Investment Opportunities
Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in state. You can also try the Theme Ratings module to determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance.
Other Consideration for investing in Acasti Stock
If you are still planning to invest in Acasti Pharma check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Acasti Pharma's history and understand the potential risks before investing.
| Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
| Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk | |
| Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals | |
| Crypto Correlations Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins | |
| Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
| Top Crypto Exchanges Search and analyze digital assets across top global cryptocurrency exchanges | |
| Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm | |
| Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
| Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. |